IVD Infectious Disease Market Size, Share, Growth, and Industry Analysis, By Types (Biochemical Diagnosis, Immune Diagnosis, Molecular Diagnosis, Microbiological Diagnosis, Urine Diagnosis, Coagulation Diagnosis, Other), By Applications Covered (Personal, Commercial, Academic, Other), Regional Insights and Forecast to 2033

IVD Infectious Disease Market Size

The IVD Infectious Disease market was valued at USD 4.73 billion in 2024 and is projected to reach USD 5.13 billion in 2025, ultimately growing to USD 9.78 billion by 2033. This growth represents a compound annual growth rate (CAGR) of 8.4% during the forecast period from 2025 to 2033.

The US IVD infectious disease market is a major segment, driven by advanced healthcare infrastructure, high demand for rapid diagnostics, and innovations in molecular and point-of-care testing. It holds a dominant share in the global market.

The IVD infectious disease market is witnessing significant growth, driven by rising demand for advanced diagnostic tools and innovations in technology. The market is expected to continue expanding due to the increasing prevalence of chronic and infectious diseases, growing healthcare investments, and the shift towards personalized medicine. Technologies such as biochemical, immune, molecular, microbiological, urine, and coagulation diagnostics are essential drivers of this growth. The global market share for these diagnostic types varies, with molecular diagnostics gaining a notable percentage of market share. Regional dynamics are also shaping the market, with North America leading the market share, followed by robust growth in the Asia Pacific region. By 2033, the market is expected to reach a substantial size, reflecting ongoing advancements and a broadening scope of applications.

IVD Infectious Disease Market Trends

The IVD infectious disease market is witnessing several key trends that are shaping its future trajectory. The increasing adoption of point-of-care testing (POCT) solutions is a significant trend, with the demand for on-site diagnostics growing rapidly. POCT devices, such as portable diagnostic kits, are becoming increasingly popular among consumers and healthcare providers alike. Additionally, technological advancements in molecular diagnostics, including PCR and next-generation sequencing, are improving the speed and accuracy of diagnostics, contributing to market growth. Personalized medicine is also a key driver of the market, as there is a rising demand for diagnostic tools tailored to individual genetic profiles. This trend is leading to the development of more effective treatments and the reduction of adverse effects. Furthermore, regulatory bodies are approving an increasing number of new diagnostic devices, enhancing market confidence. In 2023, over 100 new IVD devices were approved, reflecting growing confidence in the IVD sector. In terms of regional insights, North America holds the largest market share at around 43%.

IVD Infectious Disease Market Dynamics

The dynamics of the IVD infectious disease market are shaped by various factors influencing both its growth and challenges. One of the primary drivers of the market is the rising incidence of chronic and infectious diseases, which is contributing to a higher demand for diagnostic tests. This trend is particularly evident in regions with aging populations, where chronic diseases are becoming more prevalent. Another key factor driving market growth is technological advancements. The introduction of sophisticated diagnostic tools such as molecular diagnostics and automated devices is improving the accuracy and efficiency of disease detection. Additionally, governments around the world are supporting the development and adoption of advanced IVD technologies through funding and policy initiatives. On the other hand, market challenges include high costs associated with diagnostic devices.

DRIVER

"Rising Prevalence of Infectious Diseases"

The increasing global prevalence of infectious diseases is a primary driver of growth in the IVD infectious disease market. According to the World Health Organization (WHO), infectious diseases account for a significant proportion of global morbidity and mortality, with millions of people worldwide affected by diseases such as influenza, tuberculosis, HIV, and emerging infections like COVID-19. The ongoing threat of pandemics and antibiotic-resistant infections is increasing the demand for rapid, reliable diagnostic tests. In 2023, the global infectious disease diagnostics market experienced a surge due to COVID-19 testing, which is expected to sustain interest in IVD solutions for future outbreaks. Furthermore, rising awareness of early detection and treatment has pushed healthcare systems to adopt advanced diagnostic technologies, including molecular and point-of-care diagnostics.

RESTRAINT

"High Costs and Limited Accessibility"

One of the significant challenges faced by the IVD infectious disease market is the high cost of diagnostic tests and equipment. For instance, molecular diagnostics like PCR tests and next-generation sequencing (NGS) require costly infrastructure and specialized reagents. These costs can be prohibitive, particularly in developing countries or regions with limited healthcare budgets. A report from the National Institutes of Health (NIH) highlighted that some molecular diagnostic tests can cost upwards of $100 per test, which may limit access in resource-constrained settings. Additionally, regulatory hurdles and the lengthy approval processes for new diagnostics can delay market introduction and increase operational costs, further inhibiting growth in certain markets.

OPPORTUNITY

"Integration of Artificial Intelligence and Automation"

The integration of artificial intelligence (AI) and automation into IVD technologies presents a significant opportunity for growth. AI-enabled diagnostic tools can enhance the accuracy of disease detection and improve decision-making by processing vast amounts of clinical data quickly and effectively. The implementation of AI in molecular diagnostics, such as genetic sequencing, is expected to reduce diagnostic errors and increase the efficiency of laboratories. AI-powered platforms are also being used for predictive analytics, helping healthcare providers anticipate disease outbreaks and manage patient care. The market for AI-driven diagnostic solutions is expanding rapidly, with a projected increase in adoption among hospitals and clinics seeking to streamline operations and enhance diagnostic capabilities.

CHALLENGE

" Regulatory and Compliance Issues"

One of the main challenges in the IVD infectious disease market is navigating the complex regulatory landscape. Regulatory bodies, such as the U.S. FDA and European Medicines Agency (EMA), impose stringent requirements on diagnostic devices, which can delay the approval process and increase time-to-market. For example, the FDA requires extensive clinical validation and performance studies for new IVD products, which can take several years to complete. Additionally, the need for constant compliance with regulatory standards during the product lifecycle adds a layer of complexity to market entry, especially for new companies and small enterprises. 

Segmentation Analysis

The IVD infectious disease market is segmented based on diagnostic types and applications, each contributing significantly to market growth. The key types include biochemical diagnosis, immune diagnosis, molecular diagnosis, microbiological diagnosis, urine diagnosis, coagulation diagnosis, and others, with each segment offering unique benefits and responding to specific market needs. Applications span personal, commercial, academic, and other sectors, reflecting the diverse uses of IVD technologies in various healthcare and research settings. Each segment has its own growth dynamics, with demand driven by factors such as disease prevalence, technological advancements, and the increasing adoption of personalized medicine.

By Type

• Biochemical Diagnosis: Biochemical diagnosis involves the use of chemical tests and assays to detect infectious agents and disease markers. This segment is widely used in clinical laboratories for routine screening of diseases such as diabetes and kidney dysfunction, in addition to infectious diseases. Biochemical tests offer advantages in terms of simplicity and cost-effectiveness, making them an essential tool in resource-limited settings. The biochemical diagnosis segment is expected to account for approximately 20% of the total IVD infectious disease market, with consistent demand for basic testing in primary healthcare and emergency settings.

• Immune Diagnosis: Immune diagnosis utilizes the body’s immune response to detect infectious diseases, relying on methods such as enzyme-linked immunosorbent assays (ELISA) and immunofluorescence tests. This segment is particularly prominent in diagnosing viral infections like HIV, hepatitis, and influenza. The immune diagnosis market is expected to represent around 25% of the total IVD market, driven by advancements in immunoassays and the growing need for rapid diagnostics in both clinical and point-of-care settings.

• Molecular Diagnosis: Molecular diagnostics, including techniques like polymerase chain reaction (PCR), are essential for the detection of specific genetic material from pathogens. This segment is gaining substantial market share due to its ability to identify diseases at an early stage and offer highly accurate results. Molecular diagnosis plays a critical role in detecting infectious diseases such as COVID-19, tuberculosis, and various viral and bacterial infections. It is projected to contribute nearly 30% to the overall IVD infectious disease market, reflecting its growing adoption in clinical settings and healthcare systems globally.

• Microbiological Diagnosis: Microbiological diagnosis involves culturing and identifying pathogens from samples like blood, urine, or tissue. This method is crucial for diagnosing bacterial infections and guiding appropriate antibiotic treatment. While it is a traditional diagnostic method, it continues to play an essential role in infectious disease diagnosis, particularly for bacterial infections that are not easily detected by molecular methods. The microbiological diagnosis segment is anticipated to account for approximately 15% of the market, with stable demand from clinical microbiology laboratories.

• Urine Diagnosis: Urine diagnosis is used primarily to detect urinary tract infections (UTIs) and kidney-related diseases. Diagnostic tests like urine culture and dipstick tests are commonly used in primary care settings for rapid detection of infections. The segment is expected to contribute around 5% to the total IVD market, driven by increasing incidences of UTIs and the demand for non-invasive diagnostic options. Urine diagnosis is increasingly favored for its simplicity, cost-effectiveness, and ease of use in outpatient settings.

• Coagulation Diagnosis: Coagulation diagnosis focuses on evaluating the blood’s ability to clot, which is essential for managing conditions like hemophilia, thrombosis, and other bleeding disorders. The market for coagulation diagnostics is growing due to the increasing number of individuals requiring anticoagulant therapy and the rise in cardiovascular diseases. This segment is projected to account for about 3% of the IVD infectious disease market, driven by the growing need for routine testing in clinical and hospital settings.

• Other Types: The "Other" category includes a variety of diagnostic techniques not covered by the aforementioned types, such as molecular diagnostics for rare pathogens and novel diagnostic methods under development. These emerging diagnostics hold potential for expanding market applications, particularly in infectious diseases that are not commonly detected using traditional methods. The "Other" type is expected to capture around 2% of the market, though it is anticipated to grow as new technologies and diagnostic approaches emerge.

By Application

• Personal: Personal applications of IVD diagnostics are increasing rapidly, particularly with the rise of home testing kits for diseases like COVID-19, HIV, and sexually transmitted infections (STIs). This segment is projected to make up about 30% of the total IVD market, as consumers increasingly seek convenient, cost-effective solutions for monitoring their health from the comfort of their homes.

• Commercial: Commercial applications are expected to represent a significant portion of the market, accounting for around 40%. This includes diagnostic services provided by hospitals, clinics, and private laboratories. The demand for rapid, accurate diagnostic solutions in these settings is growing as healthcare providers aim to improve patient outcomes and reduce diagnostic errors, thereby expanding the commercial market for IVD solutions.

• Academic: Academic institutions and research organizations are major consumers of IVD technologies, using them for research on infectious diseases, disease pathways, and new therapeutic strategies. The academic application segment is expected to capture about 15% of the market. Research-driven demand is growing as the need for more accurate and effective diagnostic tools increases in the academic and clinical research communities.

• Other: The "Other" category includes non-traditional applications, such as government agencies, non-profit organizations, and the military, which use IVD technologies for monitoring and controlling disease outbreaks. This segment is projected to contribute approximately 15% of the overall market. The growing focus on global health initiatives and preparedness for pandemics is expected to drive further adoption of IVD technologies in these sectors.

Regional Outlook

The IVD infectious disease market is geographically diverse, with varying growth trends across regions. North America is the leading region in terms of market share, driven by a high level of healthcare infrastructure, strong investments in diagnostic technology, and a large number of ongoing clinical research initiatives. Europe also holds a significant share, with a growing emphasis on molecular diagnostics and regulatory advancements. The Asia-Pacific region is projected to see substantial growth due to increasing healthcare investments, rising disease prevalence, and expanding healthcare infrastructure. Meanwhile, the Middle East and Africa show potential for growth, with emerging healthcare needs and improving healthcare access.

North America

North America is the largest market for IVD infectious disease diagnostics, holding approximately 43% of the global market share. This region benefits from advanced healthcare systems, high diagnostic test adoption rates, and significant government support for healthcare innovation. The United States, in particular, dominates the region, driven by a high demand for advanced molecular diagnostics and rapid point-of-care testing solutions. As healthcare spending continues to rise, particularly on diagnostic services, North America remains a key driver of the global IVD infectious disease market.

Europe

Europe accounts for around 30% of the global IVD infectious disease market. The market in this region is bolstered by strong healthcare infrastructures and a high level of healthcare spending. The European market is particularly focused on molecular diagnostics and innovations in immunoassays. Countries such as Germany, France, and the United Kingdom are leaders in adopting advanced diagnostic technologies. Regulatory advancements and growing government support for healthcare initiatives are also contributing to the market's expansion in Europe, with an emphasis on improving the detection and treatment of infectious diseases.

Asia-Pacific

The Asia-Pacific region is one of the fastest-growing markets for IVD infectious disease diagnostics, capturing approximately 20% of the global market. This growth is attributed to the rapid expansion of healthcare infrastructure, increasing disease burden, and greater investments in healthcare technology. Countries like China, India, and Japan are witnessing growing demand for molecular diagnostics and point-of-care testing due to their large populations and increasing healthcare needs. As healthcare systems in these countries continue to improve, the adoption of IVD technologies is expected to rise, contributing significantly to the region's market share.

Middle East & Africa

The Middle East and Africa region account for around 7% of the global IVD infectious disease market. Despite being a smaller market share, the region is witnessing steady growth driven by expanding healthcare access and increasing investments in healthcare infrastructure. Rising disease prevalence and the need for improved diagnostic solutions are further fueling the demand for IVD technologies in the region. Countries such as Saudi Arabia, the United Arab Emirates, and South Africa are at the forefront of these developments, with increasing adoption of diagnostic technologies to address local healthcare needs.

List of Key IVD Infectious Disease Market Companies Profiled

• Abbott Laboratories
• Gen-Probe
• Becton Dickinson (BD)
• Bio-Rad Laboratories
• Siemens Healthcare
• Biomérieux
• Danaher
• Thermo Fisher
• Sysmex

The two top companies in the IVD infectious disease market with the highest share 

• Abbott Laboratories – holds approximately 25% of the global market share.
• Siemens Healthcare – captures around 15% of the market share.

Investment Analysis and Opportunities

The IVD infectious disease market presents a range of investment opportunities, driven by technological advancements and an increasing demand for diagnostic solutions. Investors are particularly interested in the molecular diagnostics segment, which has shown a steady rise in adoption due to its ability to detect diseases at earlier stages with greater accuracy. The global shift toward personalized medicine is also a major investment opportunity, as diagnostics tailored to individual genetic profiles are gaining traction. Investors are increasingly supporting companies involved in developing AI-driven diagnostic tools, as these technologies enhance diagnostic precision and efficiency, particularly in high-demand markets such as North America and Europe. Additionally, emerging markets in Asia-Pacific and the Middle East & Africa present significant growth potential, driven by expanding healthcare infrastructure and rising disease prevalence. Governments and private investors are capitalizing on these trends by funding innovations and expanding access to affordable diagnostic tests. As healthcare systems in regions like India, China, and Africa continue to evolve, the demand for cost-effective and rapid diagnostic solutions is expected to rise. 

New Products Development

In 2023 and 2024, there has been significant development of new products in the IVD infectious disease market, with many companies focusing on advancing diagnostic capabilities. One notable development is Abbott Laboratories' introduction of its next-generation molecular diagnostics platform, which offers faster and more accurate results for infectious diseases like COVID-19 and influenza. The new platform has been designed to streamline testing in both clinical and point-of-care settings, addressing the growing need for rapid diagnostics. Similarly, Siemens Healthcare launched a new immunoassay system that enhances the detection of viral and bacterial infections, offering improved sensitivity and specificity compared to previous models. Bio-Rad Laboratories has also made strides with the release of a new multiplex PCR test for infectious diseases, enabling the simultaneous detection of multiple pathogens in a single sample, which increases testing efficiency. Additionally, Thermo Fisher Scientific introduced an upgraded version of its laboratory automation system, which incorporates artificial intelligence to accelerate diagnostic workflows. 

Recent Developments by Manufacturers in IVD Infectious Disease Market 

• Abbott Laboratories introduced a new molecular diagnostic system in 2023 that reduces testing time for viral infections like COVID-19 and influenza by 50%, improving throughput and accessibility in healthcare settings.
• Siemens Healthcare launched a new immunoassay system in 2024, enhancing the detection capabilities for a range of viral and bacterial infections, with an emphasis on rapid testing for high-volume clinical environments.
• Bio-Rad Laboratories released an advanced multiplex PCR test in 2023, enabling healthcare professionals to detect multiple infectious pathogens simultaneously, reducing the need for separate tests and increasing diagnostic efficiency.
• Thermo Fisher Scientific unveiled an upgraded laboratory automation platform in 2024, incorporating AI to optimize workflows in clinical laboratories, improving testing accuracy and speed.
• Sysmex introduced a new coagulation analyzer in 2023 designed to provide more accurate and rapid results for diagnosing bleeding and clotting disorders, helping clinicians make faster treatment decisions.

Report Coverage of IVD Infectious Disease Market

This report provides a comprehensive analysis of the IVD infectious disease market, covering key market segments by diagnostic type, application, and region. The market is segmented into seven types, including biochemical diagnosis, immune diagnosis, molecular diagnosis, microbiological diagnosis, urine diagnosis, coagulation diagnosis, and other, with molecular diagnosis and immune diagnosis leading the market share at 30% and 25%, respectively. By application, commercial use is the dominant sector, holding around 40% of the market share, followed by personal applications at 30%. Regional insights highlight North America's leading position with a share of 43%, followed by Europe at 30%, and Asia-Pacific at 20%. Emerging markets such as the Middle East & Africa account for approximately 7% of the global market. The report also explores key players, market dynamics, and recent trends shaping the market’s future, offering a detailed forecast through 2033.